Loading
Biovie Inc. Stock: price and insider trades · United States
4 insiders bought €42k of shares over the last 90 days, the latest filed 28 Aug 2026.
Biovie Inc.: what insiders have been doing
This page follows insider dealings at Biovie Inc. as filed with SEC (Form 4), a company from the Healthcare & Pharma sector. The last twelve months, up to 18 October 2026, brought 4 filings signed by 4 insiders.
Only purchases show up on the open market, 4 purchases in all worth €42k, filed by 4 insiders. Unlike grants, an open-market purchase is paid for by the insider, at the market price. The buyers include 2 senior executives, 1 finance chief and 1 chief executive. One trade stands out by size: a purchase of €27k from Do Cuong V, disclosed on 28 August 2026.
Across the 5,458 companies tracked on its exchange, the median is 22 filings; at 4 filings, this issuer sits below that mark. Our records for Biovie Inc. go back to 2021, with 8 purchases and 4 sales on the open market in total.
In all, 4 purchases were made within 30 days of a purchase by another insider of the company. A cluster is several different insiders buying the same stock within a short window, a pattern studied more closely than a single purchase. The clock since the last published purchase (28 August 2026) now reads 51 days.
In the same sector, recent insider purchases at Anixa Biosciences Inc and Vivos Inc also feature in our signals. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Insider Decl.
46
Thresholds
n/a
Buy Volume
€67,913
8 ops. · all time
Sell Volume
€115,849
4 ops. · all time
Who traded when
BuySaleCuong do V2 buys
Amy Suzon Chappell1 buy
Joanne Wendy Kim1 buy
Joseph M. Palumbo1 buy
Since the insiders bought
- -32.5%Entry US$2.28 · Close at T+30 US$1.54
- -32.5%Entry US$2.28 · Close at T+30 US$1.54
- -32.5%Entry US$2.28 · Close at T+30 US$1.54
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2026FY ended June 2026 · cache
US$1.20
Analyst consensus
2 analystsUS$5.00Target US$5.26(+338%)US$5.51
Income statement
EBITDA-US$21.9M
Net income-US$22.1M0.0% margin
Valuation
PER (forward)-2.1x
P/Book0.9x
Beta0.73
Balance sheet & cash
Market capUS$10.4M
Total debtUS$275.4k
Free Cash Flow-US$19M
Debt / Equity3%
Profitability & ownership
ROE-150.8%
ROA-79.1%
% insiders0.5%
% institutions22.1%
Last declaration on 28 August 2026
Declarations46 total
15,210 shares@ US$2.0837.8% of flowCommon StockSEC:0001520138-26-000378:0
Canonical exit: 25 Nov 2026 (T+90)
2,500 shares@ US$2.1816.5% of flowCommon StockSEC:0001520138-26-000379:0
Canonical exit: 26 Nov 2026 (T+90)
727 shares@ US$2.16100.0% of flowCommon StockSEC:0001520138-26-000382:0
Canonical exit: 26 Nov 2026 (T+90)
4,843 shares@ US$2.1638.8% of flowCommon StockSEC:0001520138-26-000383:0
Canonical exit: 26 Nov 2026 (T+90)
5,000 sharesCommon StockSEC:0001520138-25-000251:0
Canonical exit: 5 Nov 2025 (T+90)
34,200 shares0Common StockSEC:0001520138-25-000024:0
32,700 shares0Common StockSEC:0001520138-25-000026:0
2,476 shares@ US$5.5147.4% of flowCommon StockSEC:0001520138-24-000241:0
2,476 shares@ US$5.5127.7% of flowCommon StockSEC:0001520138-24-000240:0
4,953 shares@ US$5.5136.4% of flowCommon stockSEC:0001520138-24-000239:0
10,000 sharesCommon stockSEC:0001520138-24-000099:0
Canonical exit: 2 Jun 2024 (T+90)
5,000 shares0Common StockSEC:0001520138-23-000547:0
42,254 shares0Common StockSEC:0001520138-23-000533:0
42,254 shares0Common StockSEC:0001520138-23-000532:0
46,358 shares0Common StockSEC:0001520138-23-000534:0
51,830 shares0Common StockSEC:0001520138-23-000530:0
10,000 shares@ US$1.7822.6% of flowCommon stockSEC:0001520138-23-000522:0
Canonical exit: 28 Feb 2024 (T+90)
8,560 shares@ US$3.05100.0% of flowCommon StockSEC:0001520138-23-000371:0
10,805 shares@ US$3.500938.1% of flowCommon StockSEC:0001520138-23-000347:0
149,500 shares0Common StockSEC:0001520138-23-000275:0
41,506 sharesCommon StockSEC:0001520138-23-000269:0
5,000 shares@ US$6.501232.9% of flowCommon StockSEC:0001520138-23-000264:0
3,371 shares@ US$8.51729.0% of flowCOMMON STOCKSEC:0001520138-23-000187:0
2,476 shares@ US$6.12100.0% of flowCOMMON STOCKSEC:0001520138-23-000109:0
2,476 shares@ US$6.12100.0% of flowCOMMON STOCKSEC:0001520138-23-000111:0
25 of 46 declarations
About Biovie Inc.
BioVie Inc. is a U.S.-based biopharmaceutical company listed on the NASDAQ Capital Market in the United States under the symbols BIVI and BIVIW. The company is headquartered in Carson City, Nevada, and is classified as a clinical-stage developer focused on innovative drug therapies for neurological and neurodegenerative disorders as well as advanced liver disease. BioVie was formerly known as NanoAntibiotics, Inc., a name change that reflected a strategic shift away from its earlier identity toward a more targeted life-sciences platform centered on inflammation-related disease pathways and unmet medical needs.
BioVie’s business model is that of a clinical-stage biotech: it does not yet operate as a diversified commercial pharma company with meaningful marketed-product revenue. Instead, its value proposition rests on advancing investigational assets through preclinical and clinical development, then ultimately navigating regulatory review and commercialization. Its main asset is NE3107, also known by the approved generic name bezisterim, an orally administered small molecule being studied for its potential to modulate inflammation, insulin resistance, and inflammatory cascades implicated in neurodegenerative disease. In parallel, BioVie is developing programs in advanced liver disease, giving the company a dual-therapeutic focus that spans neurology and hepatology.
Read moreShow less
From a competitive standpoint, BioVie operates in highly crowded and scientifically demanding markets. In neurodegeneration, it competes indirectly with large pharmaceutical companies, specialty biotechs, and research programs pursuing Alzheimer’s disease and related inflammatory mechanisms. In liver disease, it faces similarly intense competition from companies with deeper pipelines and larger balance sheets. BioVie’s differentiation lies in its mechanism-driven approach and in targeting diseases with substantial unmet need, but the company remains exposed to the standard biotech risks: clinical trial failure, regulatory setbacks, dilution risk, and ongoing capital requirements. Its geographic footprint is predominantly U.S.-based, with corporate and operational presence in Nevada, while the NASDAQ listing gives it access to U.S. capital markets and broader international investor visibility.
Recent corporate developments underscore the company’s financing-heavy profile. In August 2025, BioVie completed a public offering of units and warrants that raised approximately $12 million, illustrating the company’s reliance on external capital to fund development and corporate operations. Recent SEC filings also indicate ongoing litigation-related disclosures tied to prior company communications and alleged misstatements concerning clinical programs and prospects. For investors in France, Belgium, and Switzerland, BioVie should therefore be viewed as a high-risk, event-driven biotech name whose valuation will likely depend on clinical readouts, financing discipline, and the company’s ability to advance bezisterim and its liver-disease programs without excessive dilution.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
